Objective: This study aimed to investigate the clinical characteristics and prognostic significance of monosomal karyotypes (MKs) in patients with acute myeloid leukemia (AML).

Materials and Methods: We retrospectively analyzed the clinical data for 498 patients with AML, of whom 233 (46.8%) had an abnormal karyotype, including 42 with MKs (8.4%) and 70 with a complex karyotype (CK) (14.1%).

Results: Patients with MKs were older (median age 62.5 vs. 52 years, p=0.003) and had lower median hemoglobin levels (62.5 vs. 77 g/L, p=0.009) and lower white blood cell counts (7.0×10^9/L vs. 11.7×10^9/L, p=0.008). Univariate analysis showed that patients with MKs or CKs had shorter overall survival than patients without these karyotypes (median survival time 7.3 vs. 26.3 months for MK, p<0.001, and 14.8 vs. 26.3 months for CK, p<0.001). In multivariable analysis for overall survival, MK and National Comprehensive Cancer Network prognostic group were the only significant factors.

Conclusion: MK is an independent risk factor for poor prognosis in AML patients.

Keywords: Leukemia, Monosomal karyotype, Prognosis

Amaç: Bu çalışmada akut myeloid lösemi (AML) hastalarda monozomal karyotip (MK) sahip olmanın klinik özellikleri ve prognostik önemini araştırılmıştır.

Gereç ve Yöntemler: Retroスペktif olarak 498 AML hastasının klinik ve genetik verileri incelenmiştir. Hastaların %46,8'si anormal karyotip sahiptir, bunlardan %8,4'ü MK ve %14,1'ü kompleks karyotip (KK) oluşturur. MK sahip hastaların yaş ortalaması daha yüksek (62,5 vs. 52 yıl; p=0,003) ve daha düşük ortanca hemoglobin düzeyine (62,5 vs. 77 g/L; p=0,009) ve daha düşük beyaz küre sayısına (7,0×10^9/L vs. 11,7×10^9/L, p=0,008) sahipti. Ünlüvar analizde MK ve CK vurgulananın diğer hastalara göre toplam sağkalımı daha düşük bulundu. (MK için ortanca sağkalım süresi 7,3 vs. 26,3 ay, p<0,001 ve CK için 14,8 vs. 26,3 ay, p<0,001). Toplam sağkalım vurgulananın, multivariable analizde ise MK ve "National Comprehensive Cancer Network" prognostik grubu anlamlı bulunan faktördür.

Sonuç: AML’li hastalarda MK kötü prognoza işaret eden bağımsız bir risk faktörüdür.

Anahtar Sözcükler: Lösemi, Monozomal karyotip, Prognoz

Introduction

Acute myeloid leukemia (AML) is a malignant clonal disease originating from myeloid hematopoietic stem/progenitor cells, with high heterogeneity in terms of clinical manifestations, histopathology, cytogenetics, molecular genetics, and immunophenotypes. Accurate evaluation of the prognosis of patients with AML is important for establishing clinical therapeutic protocols. About 50%–60% of AML patients have cytogenetic abnormalities. A complex karyotype (CK) is an independent unfavorable prognostic factor in AML patients, and recent studies have demonstrated that patients with a monosomal karyotype (MK) have shorter survival than those with CKs [1,2,3]. However, MK has not been included in the traditional prognostic scoring systems. This study investigated the prognostic significance of MKs and CKs in a cohort of 498 patients with AML.

Materials and Methods

Study Samples and Data Sources

The study was approved by the Ethics Committees of Yuhuangding Hospital and was conducted according to the
guidelines of the Declaration of Helsinki. Due to recent wide application of cytogenetic analysis in our hospital, a total of 498 patients diagnosed with AML from July 2001 to July 2013 were included in this study. All patients were strictly reevaluated according to the 2008 World Health Organization criteria [4]. Standard daunomycin (DA) (DA at 45 mg/m²/day for 3 days plus cytosine arabinoside at 150 mg/m²/day for 7 days) or mitoxantrone (MA) (MA at 6-8 mg/m²/day for 3 days plus cytosine arabinoside at 150 mg/m²/day for 7 days) protocols were given to 452 patients as induction therapy. The clinical efficacy was evaluated according to the revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in AML [5]. For patients who achieved a complete response (CR), the above two regimens were continued, or regimens based on moderate-dose cytosine arabinoside at 2 g/m²/day for 3 days were used for consolidation and intensification therapies. Patients without CR received MAC (mitoxantrone at 6-8 mg/m²/day for 3 days plus cytosine arabinoside at 150 mg/m²/day for 7 days plus cyclophosphamide at 400 mg/m²/day on days 2 and 5) or FLAG (fludarabine at 30 mg/m²/day for 5 days plus cytosine arabinoside at 1-2 g/m²/day for 5 days plus recombinant granulocyte-colony stimulating factor at 300 µg/day for 5 days) as a second induction therapy. Forty-six (9.2%) patients were treated with palliative therapies, mainly including blood transfusion and hydroxycarbamide, to reduce white blood cells. All patients were followed up to 31 March 2014. The median follow-up time was 24 months (range: 2-145 months). The overall survival (OS) time was defined as the time from diagnosis to the last date of follow-up or the date of death.

Cytogenetic Analysis

Cytogenetic analysis was performed at first diagnosis for all patients. Bone marrow cells were collected from all patients and cultured for 24-48 h, and then used for routine preparation of slices for banding of G fragments. Karyotypes were determined according to the International System for Human Cytogenetic Nomenclature (ISHCN 2009). One abnormal clone was defined as cells with ≥20 nuclear metakinesis phases and ≥2 cells with the same chromosome increase or structural rearrangement, or ≥3 cells with the same chromosome deletion in chromosome detection. MK was defined as ≥2 distinct autosomal monosomies or one autosomal monosomy combined with an abnormal structure in one clone [1], and CK was defined as ≥3 chromosome abnormalities in one clone [6].

Statistical Analysis

Clinical and laboratory parameters at diagnosis or first referral were analyzed statistically using SPSS 18.0. Numerical variables were summarized as medians and ranges. Categorical variables were compared using chi-square statistics, and continuous variables were compared between different categories using Mann-Whitney U tests. Survival was measured from the date of diagnosis to the date of death or the last known follow-up and estimated using the Kaplan-Meier method. Survival data were compared using log-rank tests. Multivariate analysis was conducted using a Cox proportional hazards regression model. All p-values were two-tailed and statistical significance was set at p<0.05.

Results

Clinical and Laboratory Characteristics of Patients with Monosomal Karyotypes

Of the 498 patients with AML, 271 (54.4%) were males and 227 (45.6%) were females, with a median age of 54 years (12-89 years). Twenty-two (4.4%) patients had a history of myelodysplastic syndrome or myeloproliferative neoplasms. All patients had analyzable chromosome karyotypes. Of the 498 AML patients, 233 (46.8%) had abnormal karyotypes, including 42 with MKs (8.4% of all patients and 18.0% of those with an abnormal karyotype) and 70 with CKs (14.1% of all patients and 30.0% of those with an abnormal karyotype). In addition, of the 42 patients with MKs, 36 (85.7%) also met the criteria for CK, while 36 of the 70 patients with CKs (51.4%) also met the criteria for MK. Compared with patients without MKs, patients with MKs were older and had lower hemoglobin levels and lower white blood cell counts. Moreover, AML patients with histories of myelodysplastic syndrome or myeloproliferative neoplasms were more likely to have MKs than de novo AML patients (p=0.038).

Of the 42 patients with MKs, 15 had one chromosome monosomy concomitant with structural abnormality and 27 (64.3%) had ≥2 chromosome monosomies. The most common monosomies were -7 (12 cases, 28.6%), -17 (9 cases, 21.4%), -20 (7 cases, 16.7%), and -5 (6 cases, 14.3%) (Table 1).

Treatment Effect Analysis

Of the 498 AML patients, 11 died of severe pre-chemotherapeutic complications, including three patients with MKs and eight patients without MKs. Thirty-five (7.1%) patients were treated with palliative therapy. Of the 452 (90.8%) AML patients treated with induction therapy, 35 (7.7%) had MKs and 417 (92.3%) were without MKs. CR was achieved in 20% of patients with MKs compared with 61.4% of patients without MKs. Patients with MKs had significantly shorter OS than those without MKs (p<0.001). There was no difference in the outcome of patients with one monosomy combined with one structural abnormality and those with 2 monosomies (p=0.226).
Table 1. The clinical features of patients with acute myeloid leukemia

|                  | AML, n (%) | MK-, n (%) | MK+, n (%) | p-value |
|------------------|------------|------------|------------|---------|
| No.              | 498        | 456        | 42         |         |
| Sex              |            |            |            |         |
| Male             | 271 (54)   | 245 (54)   | 26 (62)    | 0.309   |
| Age, years       |            |            |            |         |
| Median (range)   | 54 (12-89) | 52 (12-89) | 62.5 (26-87)| 0.003   |
| ≤60              | 321 (64.5) | 301 (66.0) | 20 (47.6)  | 0.017   |
| >60              | 177 (35.5) | 155 (34.0) | 22 (52.4)  |         |
| WBC count, x10^9/L |           |            |            |         |
| Median (range)   | 11.0 (0.19-386.5) | 11.7 (0.19-386.5) | 7.0 (0.32-59) | 0.008 |
| ≤100             | 439 (88.2) | 397 (87.1) | 42 (100)   | 0.026   |
| >100             | 59 (11.8)  | 59 (12.9)  | 0          |         |
| Hemoglobin, g/L  |            |            |            |         |
| Median (range)   | 77 (22-148) | 77 (22-146) | 62.5 (32-148) | 0.009 |
| ≤60              | 119 (23.9) | 99 (21.7)  | 20 (47.6)  | 0.000   |
| >60              | 379 (76.1) | 357 (78.3) | 22 (52.4)  |         |
| Platelets, x10^9/L |           |            |            |         |
| Median (range)   | 39.5 (1-627) | 39 (1-627) | 44.5 (4-394) | 0.375 |
| ≤100             | 419 (84.1) | 384 (84.2) | 35 (83.3)  | 0.882   |
| >100             | 79 (15.9)  | 72 (15.8)  | 7 (16.7)   |         |
| LDH [U/L, median (range)] | 378 (81-5986) | 372 (81-5986) | 474 (147-2103) | 0.395 |
| MDS/MPN history  |            |            |            |         |
| Yes              | 22 (4.4)   | 17 (3.7)   | 5 (11.9)   |         |
| No               | 476 (95.6) | 439 (96.3) | 37 (88.1)  |         |
| CK               |            |            |            |         |
| Yes              | 70 (14.1)  | 34 (7.5)   | 36 (85.7)  | 0.000   |
| No               | 428 (85.9) | 422 (92.5) | 6 (14.3)   |         |
| NCCN grouping    |            |            |            |         |
| Better risk      | 50 (10.4)  | 50 (11.0)  | 0          | 0.000   |
| Intermediate risk| 353 (70.9) | 350 (76.7) | 3 (7.1)    |         |
| Poor risk        | 95 (19.1)  | 56 (12.3)  | 39 (92.9)  |         |

AML: Acute myeloid leukemia, MK: monosomal karyotype; WBC: white blood cell, LDH: lactate dehydrogenase, MDS/MPN: myelodysplastic syndrome/myeloproliferative neoplasms, CK: complex karyotype, NCCN: National Comprehensive Cancer Network.

Prognostic Significance of Monosomal Karyotypes in Acute Myeloid Leukemia Patients

Univariate analysis indicated that OS was poorer in patients with MKs compared with those without (median survival time 7.3 vs. 26.3 months, p<0.001) (Figure 1) and in patients with CKs compared with those without (median survival time 14.8 vs. 26.3 months, p<0.001) (Figure 2). Age (p=0.017) and National Comprehensive Cancer Network (NCCN) prognostic grouping (p<0.001) were also identified as prognostic factors in AML patients. CK, MK, and NCCN prognostic group were included in a Cox regression risk model analysis, which identified MK as a prognostic factor independent of NCCN prognostic grouping in AML patients (Table 2). The results indicated that MK, rather than CK, was a risk factor for poor prognosis in AML patients.

Discussion

Breems et al. [1] previously showed that AML patients aged 15–60 years with MKs had a poorer prognosis than those with CKs, with a 4-year OS rate of only 4%. In 2010, the Southwest Oncology Group found a similar 4-year OS rate of 3% for
Poor Prognosis in Acute Myeloid Leukemia Patients with Monosomal Karyotypes

The overall survival was poorer in patients with monosomal karyotypes than those without (median survival time 7.3 vs. 26.3 months, p<0.001). The incidence of MKs in this study was 8.4%, which was consistent with the 9%-15% reported in other studies [1,2,8,9,10,11]. MK+ AMLs were significantly associated with TP53 alterations, which appear to be one molecular basis for this purely descriptive cytogenetic subset [13].

Table 2. Analysis results using a Cox regression risk model in patients with acute myeloid leukemia.

| Factors                        | HR    | 95% CI        | p-value |
|-------------------------------|-------|---------------|---------|
| NCCN prognostic group        | 1.334 | 1.124–1.583   | 0.001   |
| MK (Y/N)                      | 2.630 | 1.847–3.743   | 0.000   |
| CK (Y/N)                      |       | 0.383         |         |
| Age (≤60 years/>60 years)      |       | 0.285         |         |

AML: Acute myeloid leukemia, HR: hazard ratio, MK: monosomal karyotype, CK: complex karyotype, NCCN: National Comprehensive Cancer Network.

Patients with MKs have a poor response to routine chemotherapy, a higher recurrence rate, and shorter long-term survival. However, some studies found that high-dose cytosine arabinoside-based chemotherapeutic regimens could improve long-term survival in MK + AML patients to some extent [15,16]. Fang et al. [17] also suggested that allogeneic hematopoietic stem cell transplantation could increase the 4-year disease-free survival rate of MK + AML patients to 25%. Although this was still lower than the 56% reported for MK - AML patients, it was obviously higher than the 3-9% for patients receiving chemotherapy alone. Subsequent studies also confirmed that transplantation could improve long-term survival in MK + AML patients, but it was associated with disadvantages such as a high recurrence rate and short median time to recurrence [2,18,19].

Conclusion

In conclusion, this study confirmed that MK was a poor prognostic factor in patients with AML independent of age, CK, and NCCN prognostic grouping. When combined with cytogenetics and NCCN prognostic grouping, MK status could further improve the prognostic classification accuracy in patients with AML.

Ethics

Ethics Committee Approval: The study was approved by the Ethics Committees of Yuhuangding Hospital.

Authorship Contributions

Concept: X.C., J.X.; Design: X.C., J.X. B.H.; Data Collection or Processing: J.X., B.H., X.L., YZ, YL, L.C., YL, N.L., X.C.; Analysis or
interpretation: JX, XL; Literature Search: JX, BH, XL, YZ, YL, LC, YL, NL, XC; Writing: JX, BH, XL, YZ, YL, LC, YL, NL, XC.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: This research was supported by the Natural Science Foundation of Shandong Province (No: ZR2015HL035, ZR2015HL074), Beijing Medical Award Foundation (YJHYXKYJJ–105), Yantai Technology Development Projects (No: 2014WS024), and Youth Foundation of Yantai Yuhuangding Hospital (No: 2014040, 201405).

References

1. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-School KB, Mellink CH, Nieuwint A, Jotterand M, Hagemeijer A, Beverloo HB, Löwenberg B. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:4791-4797.

2. Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhem S, Rummel M, Germing U, Götz K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012;119:551-558.

3. Voulatiadou G, Papaioannou G, Gaitatzis M, Lalayanni C, Syrigou A, Vadikoliou C, Saloum R, Anagnostopoulos A, Athanasiadou A. Monosomal karyotype in acute myeloid leukemia defines a distinct subgroup within the adverse cytogenetic risk category. Cancer Genet 2013;206:32-36.

4. Schiffer CA. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Semin Hematol 2008;45:3-7.

5. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doeher H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.

6. Slovak ML, Kopecky KJ, Cassetti PA, Harrington DH, Theil KS, Mohamed A, Paetta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of remission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-4083.

7. Meideiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010;116:2224-2228.

8. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.

9. Radmacher MD, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Balskus CD, Kolitz JE, Caliguri MA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006;108:1677-1683.

10. Perrot A, Luquet I, Pignereux A, Mugneret F, Delaunay J, Harousseau JL, Barin C, Cahn JY, Guardiola P, Himberlin C, Recher C, Vey N, Lioure B, Ojeda-Uribe M, Fegueux N, Berthou C, Randriamalala E, Béné MC, Iffrah N, Witz F; Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 2011;118:679-685.

11. Yang XF, Sun AN, Yin J, Cai CS, Tian XP, Qian J, Chen SN, Wu DP. Monosomal karyotypes among 1147 Chinese patients with acute myeloid leukemia: prevalence features and prognostic impact. Asian Pacific J Cancer Prev 2012;13:5421-5426.

12. Ahn HK, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high function multidrug resistance activity. Am J Hematol 2012;87:37-41.

13. Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012;119:2114-2121.

14. Gaillard JB, Chiesa J, Reboul D, Arnaud A, Bruni D, Exbrayat C, Wickenhauser S, Bourquard P, Jourdan E, Lavabre-Bertrand T. Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion. Leuk Lymphoma 2012;53:336-337.

15. Löwenberg B, Pabst T, Velenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaalma MR, Gregor M, Theobald M, Schanz U, Maertens J, Osenkopppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:1027-1036.

16. Medeiros BC, Othus M, Appelbaum FR. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:2167-2168.

17. Fang M, Storer B, Estey E, Othus M, Zhang L, Sandmaier BM, Appelbaum FR. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011;118:1490-1494.

18. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous. Biol Blood Marrow Transplant 2011;17:356-364.

19. Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y, Ago H, Takeuchi J, Nakahara H, Taguchi J, Sakura T, Takamatsu Y, Waki F, Yokoyama H, Watanabe M, Emi N, Fukuda T. Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. Haematologica 2012;97:915-918.